PEPG 241220 8.00C (PEPG241220C8000) Stock Options, News & Quotes

1.64
0.000.00%

15min DelayTrading Dec 3 10:34 ET

1.64High1.64Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Jul 30 17:12

NEWS: (No Negative Findings) PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

$PepGen (PEPG.US)$
Positive
▪️PGN-EDO51 achieved mean exon skipping levels of 2.15% after three months at 5 mg/kg dose
▪️Mean muscle-adjusted dystrophin level increased by 0.70% from baseline
▪️Mean absolute dystrophin level increased by 0.26% from baseline
▪️The 5 mg/kg dose was well-tolerated with no discontinu...

Trytosaveabit

Jul 30 16:04

Hmmm? Looks good to me?

$PepGen (PEPG.US)$ Hey Dr @Jaguar8 i need you! Hehehe. What exactly am i missing here??? I dont see it?? ((((. PepGen Shares Data From Low-Dose Cohort Of PGN-EDO51 In Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial For Treatment Of Duchenne Muscular Dystrophy; Says Was Well Tolerated, And All Patients Continued To Long-Term Extension Portion Of Trial. Dosing Of Second Cohort At 10 Mg/kg Is Ongoing
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Trytosaveabit

Mar 13 06:05

$PepGen (PEPG.US)$ PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy

Moomoo AI

Jan 17 06:09

Mary Beth DeLena's addition to PepGen's executive team is viewed positively, her vast legal and compliance experience is anticipated to significantly contribute to PepGen's aim of providing next-gen oligonucleotide therapies for severe neuromuscular and neurological diseases.

Press Release: Mary Beth DeLena Joins PepGen as General Counsel and Secretary